newsmetry
rusign inget started
macro

Vir's Hepatitis Delta Drug Hits Main Goal in Phase 3 ECLIPSE 1 Study

Vir Biotechnology says its Phase 3 ECLIPSE 1 trial reached its primary endpoint, with 44% of patients showing undetectable HDV RNA and normal ALT at Week 48.

published on Newsmetry
original source published

the same feed is available to bots and dashboards through the api. connect the api →

Newsmetry newsroom

what happened

Vir Biotechnology said its Phase 3 ECLIPSE 1 study achieved the main goal of the trial, according to a BusinessWire release reported by TradingView. By Week 48, 44% of participants had undetectable HDV RNA together with normalized ALT. The comparison group, which received delayed treatment, showed 0% at Week 12, a difference the company described as statistically significant at p<0.0001.

The key secondary endpoint, viral suppression, was also reached, with 79% of patients having undetectable virus at Week 48. The company reported one treatment-related Grade 3 adverse event, which resolved within 15 days, with no treatment interruptions or discontinuations. Data from ECLIPSE 2 and 3 are expected in Q1 2027, and a U.S. FDA submission is planned for mid-2027. Both timelines depend on all three trials and remain company plans.

why it matters

The result concerns an investigational regimen for chronic hepatitis delta and follows earlier development work and regulatory designations. Investors will now watch the ECLIPSE 2 and 3 data and the FDA submission schedule, since the filing depends on all three trials.

market impact

Shares of Vir Biotechnology: a successful Phase 3 readout supports interest in the stock

  • Vir Biotechnology shares pressure up — meeting the primary endpoint reduces uncertainty around the program

tags

StockUnited States

instruments

VIR

on polymarket

Will total votes cast in the 2026 midterm election for Senator from West Virginia be less than 400,000?0.2%Will total votes cast in the 2026 midterm election for Senator from Virginia be 4,000,000 or more?3.9%Will the Democratic Party candidate win the 2026 Virginia Senate election by 15%-18%?1%

sources

  1. Vir Biotechnology, Inc. (VIR) Phase 3 Trial Meets Primary Endpoint — TradingView, 8 November 2026 at 21:15 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗

related stories